Long-term Pulmonary Safety of Inhaled Levodopa in Parkinson's Disease Subjects with Motor Fluctuations: A Phase 3 Open-label Randomized Study

被引：0
|
作者：
Grosset, Donald
Dhall, Rohit
Gurevich, Tanya
Kassubek, Jan
Poewe, Werner
Rascol, Olivier
Rudzinska, Monika
Cormier, Jennifer
Sedkov, Alexander
Oh, Charles
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
190
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 50 条
  • [21] Long-term safety of levodopa-carbidopa intestinal gel from an ongoing, open-label, phase 3 continued access to treatment study in advanced Parkinson's disease patients
    Rodriguez, R. L.
    Zadikoff, C.
    Espay, A. J.
    Fung, V. S. C.
    Hall, C.
    Robieson, W. Z.
    Chatamra, K.
    Eaton, S.
    Facheris, M. F.
    Benesh, J.
    MOVEMENT DISORDERS, 2016, 31 : S662 - S663
  • [22] Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn's disease
    Danese, Silvio
    Beaton, Andrew
    Duncan, Elizabeth A.
    Mercier, Anne-Kristina
    Neisen, Jessica
    Seth, Henrik
    Zetterstrand, Sofia
    Sands, Bruce E.
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [23] Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s disease
    Silvio Danese
    Andrew Beaton
    Elizabeth A. Duncan
    Anne-Kristina Mercier
    Jessica Neisen
    Henrik Seth
    Sofia Zetterstrand
    Bruce E. Sands
    BMC Gastroenterology, 23
  • [24] Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
    Heinz Reichmann
    Andrew Lees
    José-Francisco Rocha
    Diogo Magalhães
    Patrício Soares-da-Silva
    Translational Neurodegeneration, 9
  • [25] Subcutaneous Levodopa Infusion for Parkinson's disease Patients with Motor Fluctuations: Open-Label Efficacy Outcomes from the BeyoND study
    Poewe, W.
    Stocchi, F.
    Adar, L.
    Case, R.
    Yardeni, T.
    Espay, A.
    MOVEMENT DISORDERS, 2021, 36 : S191 - S191
  • [26] A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
    Camporeale, Angelo
    Kudrow, David
    Sides, Ryan
    Wang, Shufang
    Van Dycke, Annelies
    Selzler, Katherine J.
    Stauffer, Virginia L.
    BMC NEUROLOGY, 2018, 18
  • [27] A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
    Angelo Camporeale
    David Kudrow
    Ryan Sides
    Shufang Wang
    Annelies Van Dycke
    Katherine J. Selzler
    Virginia L. Stauffer
    BMC Neurology, 18
  • [28] Long-term Safety and Efficacy of IPX203 in Parkinson's Disease Patients with Motor Fluctuations: A 9-Month Open-label Extension Trial
    Espay, Alberto
    Hauser, Robert
    Dhall, Rohit
    Thakkar, Sandeep
    Cloud, Leslie
    Banisadr, Ghazal
    Fisher, Stanley
    Visser, Hester
    NEUROLOGY, 2023, 100 (17)
  • [29] A phase 2, 36-week, open-label, follow-up study assessing the long-term safety and efficacy of the adenosine A2A receptor antagonist preladenant in subjects with Parkinson's disease and motor fluctuations
    Wolski, K.
    Factor, S. A.
    Togasaki, D. M.
    Huyck, S.
    Cantillon, M.
    Ho, T.
    MOVEMENT DISORDERS, 2011, 26 : S145 - S145
  • [30] Interim results of clinician-rated symptom endpoints of a long-term, open-label study of levodopa-carbidopa intestinal gel in Parkinson's disease patients with severe motor fluctuations
    Fernandez, H. H.
    Espay, A. J.
    Standaert, D. G.
    Benesh, J.
    Lenz, R. A.
    Caras, S. D.
    Pritchett, Y. L.
    Chatamra, K.
    MOVEMENT DISORDERS, 2011, 26 : S126 - S126
12345